Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Perspective Therapeutics, Inc.CATX · Entity 694 | Chief Medical Officer | March 02, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Perspective Therapeutics, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.35 · Expires 2036-03-02 | Direct | 150,000 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 150,000 · Balance 150,000 F1: The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 4, 2026, with a grant date of March 2, 2026 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2026. F2: Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 4, 2026, with a grant date of March 2, 2026 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2026.
F2: Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 4, 2026 21:34 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001965071-26-000002 · ownership.xml · derivative · entry 1 Puhlmann Markus · CIK 0001965071 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2036-03-02 F1 · date: The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 4, 2026, with a grant date of March 2, 2026 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2026. F2 · derivative.exercise_date: Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:29 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock option (right to buy) · Derivative | 165,000 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0000950170-25-033675 · ownership.xml · derivative · entry 1 Puhlmann Markus · CIK 0001965071 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2035-03-03 F1 · date: The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 13, 2025, with a grant date of March 3, 2025 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2025. F2 · derivative.exercise_date: Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:07 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $10.65 | $0.00 |
DisclosureSEC source: 0000950170-24-076710 · ownership.xml · derivative · entry 1 Puhlmann Markus · CIK 0001965071 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-06-20 F1 · derivative.exercise_date: Option vests over four years with 1/48th of the shares subject to such option vesting and becoming exercisable in substantially equal monthly installments on the monthly anniversary after the Grant Date (06/20/2024), subject to a continued service relationship. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 22:40 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 280,000 | $0.50 | $139,888.00 |
DisclosureSEC source: 0001437749-24-002324 · rdgdoc.xml · nonDerivative · entry 1 Puhlmann Markus · CIK 0001965071 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,375,425 F1 · price: This price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4871 to $0.5000, inclusive. The reporting person undertakes to provide to Perspective Therapeutics, Inc., any security holder of Perspective Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 00:09 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 400,000 | $0.34 | $137,000.00 |
DisclosureSEC source: 0001437749-23-034931 · rdgdoc.xml · nonDerivative · entry 3 Puhlmann Markus · CIK 0001965071 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,095,425 Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 00:09 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 60,419 | $0.26 | $15,461.22 |
DisclosureSEC source: 0001437749-23-034931 · rdgdoc.xml · nonDerivative · entry 2 Puhlmann Markus · CIK 0001965071 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 695,425 Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:09 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 135,006 | $0.27 | $36,276.11 |
DisclosureSEC source: 0001437749-23-034931 · rdgdoc.xml · nonDerivative · entry 1 Puhlmann Markus · CIK 0001965071 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 635,006 Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 23:44 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock Options (right to buy) · Derivative | 1,477,619 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001437749-23-034481 · rdgdoc.xml · derivative · entry 1 Puhlmann Markus · CIK 0001965071 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,885,688 Underlying: Common Stock · 1,477,619 shares Expires 2033-12-12 F1 · derivative.exercise_date: 25% vested as of 12/12/2023, and the remaining 75% will vest over the next three (3) years, commencing on 12/12/2024, until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.